@hoperugo.bsky.social
You are too funny but thanks for the kind words!! @sabcs.bsky.social is our opportunity to spread the word about @bsky.app
She’s here guys she’s here!! 🥰🥰 My beloved @hoperugo.bsky.social has joined the party!!! #bcsm take note. Our mamma bear has arrived!
November 23, 2024 at 12:46 PM
You are too funny but thanks for the kind words!! @sabcs.bsky.social is our opportunity to spread the word about @bsky.app
Great news - post #sabcs24 on bsky.social! This is the way to get our colleagues and friends on board. @sabcs.bsky.social @oncoalert.bsky.social
November 23, 2024 at 12:45 PM
Great news - post #sabcs24 on bsky.social! This is the way to get our colleagues and friends on board. @sabcs.bsky.social @oncoalert.bsky.social
We need to get the oncology community on board! Can’t deal with X!!
@hoperugo.bsky.social glad to see you here!!
November 23, 2024 at 12:42 PM
We need to get the oncology community on board! Can’t deal with X!!
Have to share this beautiful photo. @oncoalert.bsky.social
November 23, 2024 at 12:40 PM
Have to share this beautiful photo. @oncoalert.bsky.social
Thanks for posting! A favorite activity is the recordings I do with Sara Tolaney around new data at our international meetings! @oncoalert.bsky.social @ucsfcancer.bsky.social
📣JUST IN: Dr. Sara Tolaney @danafarber.bsky.social BreastOnc & Dr. Hope Rugo @hoperugo.bsky.social UCSFCancer share insights on Top #SABCS24 abstracts! Watch
📽️ on 👇
tinyurl.com/SABCS24eBC
#bcsm #oncsky #medsky #breastcancer
📽️ on 👇
tinyurl.com/SABCS24eBC
#bcsm #oncsky #medsky #breastcancer
SABCS 2024 Noteworthy Abstracts in Early Breast Cancer
A video from Sara Tolaney, posted on Nov 19, 2024.
tinyurl.com
November 23, 2024 at 12:38 PM
Thanks for posting! A favorite activity is the recordings I do with Sara Tolaney around new data at our international meetings! @oncoalert.bsky.social @ucsfcancer.bsky.social
Impact of risk reducing surg for young women with BRCA (Lambertini). Zest (Turner) about ctDNA in high risk early stage disease, what have we learned!
of course many more... @oncoalert.bsky.social
of course many more... @oncoalert.bsky.social
Agree with the list, big data coming up! - a few more here and to follow: COMET, important trial evaluating watch and wait vs surgery for low risk DCIS (Hwang). PADMA: RW study of Pablo/letrozole vs chemo for metastatic disease (Loibl).
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 19, 2024 at 2:55 AM
Impact of risk reducing surg for young women with BRCA (Lambertini). Zest (Turner) about ctDNA in high risk early stage disease, what have we learned!
of course many more... @oncoalert.bsky.social
of course many more... @oncoalert.bsky.social
Agree with the list, big data coming up! - a few more here and to follow: COMET, important trial evaluating watch and wait vs surgery for low risk DCIS (Hwang). PADMA: RW study of Pablo/letrozole vs chemo for metastatic disease (Loibl).
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 19, 2024 at 2:54 AM
Agree with the list, big data coming up! - a few more here and to follow: COMET, important trial evaluating watch and wait vs surgery for low risk DCIS (Hwang). PADMA: RW study of Pablo/letrozole vs chemo for metastatic disease (Loibl).